Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio

Sanofi’s Vicebio acquisition brings technology for developing vaccine combinations for multiple pathogens, such as RSV and hMPV. The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu. The post Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio appeared first on MedCity News.

Read More

Are 5 Million Nondisabled Medicaid Recipients Watching TV All Day? That’s Unsupported

“Almost 5 million able-bodied Medicaid recipients ‘simply choose not to work’ and ‘spend six hours a day socializing and watching television.’” Scott Jennings on “CNN NewsNight with Abby Phillip” on July 1 Republicans defended the GOP megabill’s Medicaid changes as targeting a group of people they believe shouldn’t qualify: people who can work but instead…

Read More

Healthcare AI: What’s in your chatbot?

By OWEN TRIPP So much of the early energy around generative AI in healthcare has been geared toward speed and efficiency: freeing doctors from admin tasks, automating patient intake, streamlining paperwork-heavy pain points. This is all necessary and helpful, but much of it boils down to established players optimizing the existing system to suit their…

Read More

A deeper dive into drug revenue and cost

Many people don’t understand why pharmaceuticals cost so much money. Don’t pharmaceutical companies make a lot of money? The answer is ‘yes’, but only if the drugs are successful. A paper by Wouters et al. (2024) found that: Based on data for 361 of 558 new therapeutic agents approved over the study period (median follow-up…

Read More